TAK-659 (100 mg/kg/day; p.o.; for 10 days) treatment totally abrogates splenomegaly and tumor development in LMP2A/MYC mice in both pretumor and tumor cell transfer experiments[4].
TAK-659 treatment kills tumor cells, but not host cells within the spleen and tumors[4].
TAK-659 treatment abrogates metastasis of tumor cells into bone marrow[4].
| Animal Model: | LMP2A/MYC double transgenic mice[4] |
| Dosage: | 100 mg/kg/day |
| Administration: | Oral gavage; for 10 days |
| Result: | Inhibited LMP2A-induced tumor cell survival in vivo. |
